Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Alexandrina DrutaDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Rania BouhmalaDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0009-0004-3104-4636
Teqwa RagdiDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Mariangel LunaColloids and Polymers Physics Group, Department of Physics of Particles, Faculty of Physics, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Manuel Bañobre-LópezInternational Iberian Nanotechnology Laboratory, Avenida Mestre José Veiga s/n, 4715-330 Braga, Portugal.ORCID 0000-0003-4319-2631
Christian F MasaguerDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0002-0146-5147
Manuel AmorínDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0002-2992-5555
Silvia BarbosaColloids and Polymers Physics Group, Department of Physics of Particles, Faculty of Physics, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0003-1831-1686
Pablo TaboadaColloids and Polymers Physics Group, Department of Physics of Particles, Faculty of Physics, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0002-2903-7857
Alberto CoelhoDepartment of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0001-6514-3967
Funding
Agencia Estatal de Investigación PCI2022-134981-2Agencia Estatal de Investigación PID2022-142682OB-I00Xunta de Galicia ED431C 2022/28
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
3D printingantiproliferativeHeLaheterogeneous catalysisisatinsMCF-7MDA-MD231monolithic catalystsZIF-8
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Developing Heterogeneous Porous 3D-Printed SiO · full record | OpenQuestion